RxDoctor Payments Data

Robert Long, PharmD

Advanced Heart Failure and Transplant Cardiology · Jackson, MSNPI 1639383532

Payments from drug & device makers

$1,696,730in general payments, 2019–2025

Across 1,523 payments — averaging $1114.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$428K
  • Merck$308K
  • Boehringer Ingelheim$292K
  • Livanova USA, Inc.$252K
  • Medtronic$116K
  • Bayer$99K
  • plus $202K from 42 others

What the payments were for

  • Consulting fees$86,8519%
  • Speaking & faculty fees$803,54479%
  • Travel & lodging$98,26110%
  • Food & beverage$26,5473%
  • Education$1900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$165,841
Medicare patients
932
Services billed
2,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis49$1,149,723
AdempasRiociguat62$851,758
Ambrisentan208$674,066
VyndaqelTafamidis Meglumine27$598,058
EntrestoSacubitril/Valsartan671$593,074
OpsumitMacitentan43$543,102
Orenitram ErTreprostinil Diolamine54$425,520
FarxigaDapagliflozin Propanediol528$398,601
Tyvaso DpiTreprostinil16$374,427
LetairisAmbrisentan21$270,450
WinrevairSotatercept-Csrk18$253,097
JardianceEmpagliflozin200$175,241
CamzyosMavacamten18$143,187
EliquisApixaban152$120,842
Tadalafil90$78,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$766$1,868,623228 claims
BayerAdempas$98,821$851,75862 claims
NovartisEntresto$50,212$593,074671 claims
Actelion Pharmaceuticals US, Inc.Opsumit$3,869$543,10243 claims
AstraZenecaFarxiga$427,770$398,601528 claims
GileadLetairis$108$270,45021 claims
MerckWinrevair$308,208$253,09718 claims
Boehringer IngelheimJardiance$292,054$175,241200 claims
E.r. Squibb & Sons, L.L.C.Camzyos$59,801$143,18718 claims
United Therapeutics CorporationAdcirca$755$49,08612 claims
Johnson & JohnsonXarelto$384$42,21859 claims
AmgenCorlanor$265$15,49916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Jackson

Where these figures come from

Is this you, or does something look wrong? →